SELLAS Life Sciences Group, Inc. (SLS) AI Stock Analysis

SELLAS Life Sciences Group, Inc. is an advanced biopharmaceutical company specializing in the development of cancer immunotherapies across various indications in the United States. Its lead candidate, galinpepimut-S (GPS), targets Wilms tumor 1 and is in Phase III clinical trials for acute myeloid leukemia, as well as Phase 1/2 trials for ovarian cancer. The company is also developing nelipepimut-S for early-stage breast cancer, which is in Phase 2b clinical trials. Additionally, SELLAS has partnered with Merck & Co., Inc. to evaluate GPS combined with pembrolizumab across multiple cancer types in a Phase 1/2 trial.

Annual revenue was $1,900 in FY2020, rose to $7.6M in FY2021, and declined 86.8% to $1.0M in FY2022. Net loss widened over this span, moving from -$16.8M in FY2020 to -$20.7M in FY2021 and -$41.3M in FY2022 as R&D expense expanded from $9.3M to $30.3M. In FY2022, operating margin was -4195.0% and EPS was -$1.61. For the trailing twelve months ended June 30, 2026, revenue was $0, with an operating margin of 0.0% and EPS of -$0.21. In the latest quarter, revenue declined 82.5% year-over-year.

As of June 30, 2026, SELLAS held $138.4M in cash and short-term investments against total debt of $737,000, resulting in net cash of $137.7M. The company reported a current ratio of 18.83 and a debt-to-equity ratio of 0.01. Free cash flow was -$28.3M in FY2022, down from -$10.4M in FY2020. Over a five-year period through FY2025, the company's share count increased 1090.4%.

SELLAS trades at a price-to-sales ratio of 26.9x and an enterprise value to revenue of 20.8x, both above the median of its US-listed Healthcare peers price-to-sales ratio of 4.1x. Its price-to-book ratio is 16.9x, supported by an enterprise value of $2.18B. Over the past year, the stock returned 362.0%, outperforming the S&P 500 return of 16.8%. Over a five-year period, SLS returned 13.0%, compared to 83.0% for the S&P 500.

Wall Street coverage consists of 1 Strong Buy and 1 Buy rating. The mean price target is $32.50, representing an upside of 225.7% from the last close of $9.98. For the current fiscal year ending December 31, 2026, analysts estimate EPS of -$0.20 and revenue of $0. For the next fiscal year, 2 analysts project revenue of $53.1M and an EPS of -$0.10. SELLAS has beaten EPS estimates in 3 of the last 4 quarters, with its next earnings date scheduled for November 11, 2026.

This page is an AI-written research summary of SELLAS Life Sciences Group, Inc. (SLS). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: SLS income statement, SLS balance sheet, SLS key metrics, SLS analyst forecast, SLS chart. See the SLS stock overview for the latest quote and news.